John Cullity
Director/Board Member bij HaemaLogiX Pty Ltd.
Vermogen: 8 M $ op 31-03-2024
Profiel
John Cullity is currently a Director at Theraly Fibrosis, Inc., a Non-Executive Director at HaemaLogiX Pty Ltd., a Managing Director at Biosynergy Partners LLC, and a Member at The Royal College of Physicians.
He previously worked as a Director of Health Economics at Merk Sharp & Dohme (Holdings) Pty Ltd.
and Sanofi-Aventis Healthcare Pty Ltd., a Senior Member of Business Development at Sanofi-Synthelabo, Inc., and a Principal at Torreya Partners LLC.
He also served as a Director at Ceramedix Holdings LLC and a Non-Executive Director at Race Oncology Ltd.
Dr. Cullity holds a graduate degree from the London School of Economics & Political Science, an undergraduate degree from The University of Western Australia, and an MBA from The Wharton School of the University of Pennsylvania.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
5.09% | 25-08-2023 | 8 402 194 ( 5.09% ) | 8 M $ | 31-03-2024 |
Actieve functies van John Cullity
| Bedrijven | Functie | Begin |
|---|---|---|
| Biosynergy Partners LLC | Corporate Officer/Principal | 01-09-2013 |
Theraly Fibrosis, Inc.
 Theraly Fibrosis, Inc. Pharmaceuticals: MajorHealth Technology Theraly Fibrosis, Inc. operates as a commercial physical research company. The company was founded by Seulki Lee and is headquartered in Germantown, MD. | Director/Board Member | 01-09-2016 |
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Director/Board Member | 01-01-2015 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Eerdere bekende functies van John Cullity
| Bedrijven | Functie | Einde |
|---|---|---|
| RACE ONCOLOGY LIMITED | Chairman | 20-04-2023 |
| Ceramedix Holdings LLC | Director/Board Member | 01-03-2020 |
Torreya Partners LLC
 Torreya Partners LLC Investment ManagersFinance Torreya Partners LLC engages in provision of financial advisory services. The company was founded by Tim Opler and Mark Simon in 2007 and is headquartered in New York, NY. | Corporate Officer/Principal | 01-01-2017 |
| Sanofi-Aventis Healthcare Pty Ltd. | Corporate Officer/Principal | - |
Merk Sharp & Dohme (Holdings) Pty Ltd.
 Merk Sharp & Dohme (Holdings) Pty Ltd. Pharmaceuticals: MajorHealth Technology Merk Sharp & Dohme (Holdings) Pty Ltd. develops, manufactures and markets drug therapies. The company was founded in 1958 and is headquartered in Macquarie Park, Australia. | Corporate Officer/Principal | - |
Opleiding van John Cullity
| London School of Economics & Political Science | Graduate Degree |
| The University of Western Australia | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
| Sanofi-Synthelabo, Inc. | Health Technology |
Merk Sharp & Dohme (Holdings) Pty Ltd.
Merk Sharp & Dohme (Holdings) Pty Ltd. Pharmaceuticals: MajorHealth Technology Merk Sharp & Dohme (Holdings) Pty Ltd. develops, manufactures and markets drug therapies. The company was founded in 1958 and is headquartered in Macquarie Park, Australia. | Health Technology |
Torreya Partners LLC
Torreya Partners LLC Investment ManagersFinance Torreya Partners LLC engages in provision of financial advisory services. The company was founded by Tim Opler and Mark Simon in 2007 and is headquartered in New York, NY. | Finance |
| Sanofi-Aventis Healthcare Pty Ltd. | |
| Race Oncology Ltd. | |
Theraly Fibrosis, Inc.
Theraly Fibrosis, Inc. Pharmaceuticals: MajorHealth Technology Theraly Fibrosis, Inc. operates as a commercial physical research company. The company was founded by Seulki Lee and is headquartered in Germantown, MD. | Health Technology |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |
| Biosynergy Partners LLC | |
| Ceramedix Holdings LLC |
